Blog

Amol Akhade: Does CTRT improve outcomes in gall bladder cancer?

Amol Akhade/LinkedIn

Jan 23, 2025, 14:32

Amol Akhade: Does CTRT improve outcomes in gall bladder cancer?

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared the following on X:

“Adjuvant chemo vs. chemo followed by CTRT in gall bladder cancer. Phase 3 RCT from India. Accelerate trial with 94 patients. Post-RO resection: 49 got chemo, 45 got chemo followed by CTRT. Median OS NR vs. 34.56 months. Median RFS 51.96 vs. 43.99 months.

So, the addition of CTRT to chemo alone does not improve outcomes in resected gall bladder cancer. What are your thoughts on this? A small trial, affected by the COVID pandemic, but probably with the right conclusion.”

Accelerate trial adjuvant chemotherapy Amol Akhade cancer Cancer research cancer treatment clinical trials CTRT gall bladder cancer India OncoDaily Oncology Phase 3 Trial survival outcomes

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director